The transgenic expression of human CD39 on murine islets inhibits clotting of human blood
Version 2 2024-06-03, 18:14Version 2 2024-06-03, 18:14
Version 1 2019-07-16, 13:33Version 1 2019-07-16, 13:33
journal contribution
posted on 2024-06-03, 18:14 authored by KM Dwyer, TB Mysore, S Crikis, SC Robson, H Nandurkar, PJ Cowan, AJF D'ApicePlatelet activation is believed to play an important role in the triggering of thrombosis of human blood by pig islets. We used a transgenic mouse model to investigate whether overexpression of CD39 (ecto nucleoside triphosphate diphosphohydrolase 1 [ENTPD1], EC 3.6.1.5), an ectonucleotidase that degrades the platelet agonists ATP, could interfere with this process. Islets isolated from CD39 transgenic mice showed 2.4-fold higher NTPDase activity than wild-type controls. When incubated with human blood, these islets significantly delayed clotting time compared to wild type islets (7.9±0.89 min versus 4.3±0.77 min, P=0.007). Importantly, expression of human CD39 in the islets of transgenic mice had no deleterious effect on glucose metabolism. These results suggest that transgenic expression of human CD39 does not interfere with islet function and may be a useful strategy to inhibit thrombosis induced by intraportal administration of islet xenografts. Copyright © 2006 by Lippincott Williams & Wilkins.
History
Journal
TransplantationVolume
82Pagination
428-432Location
Philadelphia, Pa.Publisher DOI
ISSN
0041-1337Language
engPublication classification
C1.1 Refereed article in a scholarly journalIssue
3Publisher
Wolters KluwerUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC